Post-earnings recap
Reported
Tue, Aug 2, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
Corcept Therapeutics reported a positive surprise on EPS, indicating better-than-expected profitability. However, the stock fell by 3.81% in reaction, suggesting that investors may have been disappointed by the lack of revenue details and guidance. The absence of management commentary also leaves uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.03 | N/A | +328.57% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—